/ /

Cheryl Guttman Krader
Gene fusions point to radiation resistance in prostate cancer
Results of in vitro studies indicate that E-twenty six (ETS) gene fusions in prostate cancer may be a biomarker of radiation resistance and a potential target for reversing radioresistance through treatment with a poly(ADP-ribose)polymerase 1 (PARP1) inhibitor.
Advanced prostate cancer survival predicted by gene panel
Results from testing in an initial patient cohort indicate the potential for a six-gene, whole blood RNA-based expression panel to predict survival in men with progressive metastatic castration-resistant prostate cancer.
Testosterone breakthrough common in patients on androgen deprivation therapy
Among men treated with curative radiation therapy and neoadjuvant, adjuvant, or concurrent androgen deprivation therapy (ADT), about one-fourth fail to achieve or maintain true castrate levels of testosterone suppression.
Videourodynamics: No added benefit in men with stress urinary incontinence
Findings from a large cohort of men with post-radical prostatectomy incontinence provide some insight on the diagnostic benefit of videourodynamic studies for guiding management decisions.
Prophylactic sling in vaginal prolapse repair decreases incontinence risk
In stress continent women, prophylactic placement of a midurethral sling at the time of vaginal prolapse repair significantly decreases the development of bothersome urinary incontinence, even after allowing for delayed incontinence intervention.
Midurethal slings found superior to mini-slings in stress urinary incontinence
Female stress urinary incontinence treatment with single-incision mini-slings yields significantly lower cure rates and higher risk of repeat surgery compared with standard midurethral slings.
Post-progression prostate cancer immunotherapy use efficacious
Results from analyses of the crossover effect of post-progression treatment in the control arms for the pivotal controlled trials of sipuleucel-T (Provenge) serve to reaffirm the efficacy of the autologous cellular immunotherapy for increasing overall survival in men with metastatic castrate-resistant prostate cancer (mCRPC).
Prior prostate cancer treatment does not preclude abiraterone use
Prior treatment with ketoconazole should not preclude subsequent use of abiraterone acetate (ZYTIGA) in men with progressive metastatic castration-resistant prostate cancer.
Circulating tumor cell level shows prognostic value in advanced prostate cancer
Quantity of circulating tumor cells appears to be a useful biomarker for prognostication in patients with metastatic hormone-sensitive prostate cancer.
Electronic medical record modification allows for automated data retrieval
Urologists at Cleveland Clinic have undertaken a pilot program involving modification of a commercial electronic medical record (EMR) system to facilitate clinical research and clinical practice outcomes analysis in a way that overcomes the obstacles presented by the record-keeping technology.


View Results